Open Access Policy
DMM is an open access journal. All articles are made freely available to readers upon publication. Our open access policy is in in accordance with the Budapest Open Access Initiative (BOAI) definition. For more information please read BOAI statement.
Article Processing Charge
All costs related to publication of your article are covered by DMM.
Peer review process
Manuscripts are accepted for consideration with the understanding that they have been submitted solely to DMM and that they have not been previously published, either in whole or in part.
DMM accepts manuscripts electronically through a manuscript submission and tracking system. Authors should register first to submit their manuscripts. You will find instructions for submission of the manuscript on the journal’s website. Please address your questions to firstname.lastname@example.org.
All articles submitted to the journal are first evaluated by one of the editors. If the articles fall in the scope of journal, they are sent to at least to reviewers. We use a single blind peer review. That is, authors do not know the identity of reviewers but reviewers know the authors. We aim to reach a decision as soon as possible. First decision is reached usually in 3 weeks.
Publishing ethics and plagiarism detection
We screen all submissions with iThenticate plagiarims detection software. Articles with significant plagiarism are immediately returned to the authors. By submitting your work to Disease and Molecular Medicine, you consent that your manuscript can be screened with plagiarism detection software.
Copyright of all material is held by the Disease and Molecular Medicine. The editors, editorial board, sponsoring organizations, and publisher do not accept responsibility for the statements expressed by authors in their contributions. Authors can use the published version of their articles for educational purposes. DMM is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Disease and Molecular Medicine is published by ScopeMed.